DNA damaging agents such as ionizing radiation or chemotherapy are frequently used in oncology. DNA damage response (DDR)-triggered by radiation-induced double strand breaks-is orchestrated mainly by three Phosphatidylinositol 3-kinase-related kinases (PIKKs): Ataxia teleangiectasia mutated (ATM), DNA-dependent protein kinase (DNA-PK) and ATM and Rad3-related kinase (ATR). Their activation promotes cell-cycle arrest and facilitates DNA damage repair, resulting in radioresistance. Recently developed specific ATR inhibitor, VE-821 (3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide), has been reported to have a significant radio- and chemo-sensitizing effect delimited to cancer cells (largely p53-deficient) without affecting normal cells. In this study, we employed SILAC-based quantitative phosphoproteomics to describe the mechanism of the radiosensitizing effect of VE-821 in human promyelocytic leukemic cells HL-60 (p53-negative). Hydrophilic interaction liquid chromatography (HILIC)-prefractionation with TiO2-enrichment and nano-liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis revealed 9834 phosphorylation sites. Proteins with differentially up-/down-regulated phosphorylation were mostly localized in the nucleus and were involved in cellular processes such as DDR, all phases of the cell cycle, and cell division. Moreover, sequence motif analysis revealed significant changes in the activities of kinases involved in these processes. Taken together, our data indicates that ATR kinase has multiple roles in response to DNA damage throughout the cell cycle and that its inhibitor VE-821 is a potent radiosensitizing agent for p53-negative HL-60 cells.

Department of Radiobiology Faculty of Health Sciences in Hradec Králové University of Defense in Brno Hradec Kralove 500 01 Czech Republic

Institute of Medical Biochemistry Faculty of Medicine in Hradec Králové Charles University Prague Hradec Kralove 500 00 Czech Republic

Institute of Molecular Pathology Faculty of Health Sciences in Hradec Králové University of Defense in Brno Hradec Kralove 500 01 Czech Republic

Zobrazit více v PubMed

Tichý A., Vávrová J., Pejchal J., Rezácová M. Ataxia-telangiectasia mutated kinase (ATM) as a central regulator of radiation-induced DNA damage response. Acta Med. Hradec Králove. 2010;53:13–17. PubMed

Gamper A.M., Rofougaran R., Watkins S.C., Greenberger J.S., Beumer J.H., Bakkenist C.J. ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage. Nucleic Acids Res. 2013;41:10334–10344. PubMed PMC

Charrier J.-D., Durrant S.J., Golec J.M.C., Kay D.P., Knegtel R.M.A., MacCormick S., Mortimore M., O’Donnell M.E., Pinder J.L., Reaper P.M., et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 2011;54:2320–2330. doi: 10.1021/jm101488z. PubMed DOI

Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., Maccormick S., Charlton P.A., Golec J.M.C., Pollard J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011;7:428–430. PubMed

Pires I.M., Olcina M.M., Anbalagan S., Pollard J.R., Reaper P.M., Charlton P.A., McKenna W.G., Hammond E.M. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br. J. Cancer. 2012;107:291–299. PubMed PMC

Prevo R., Fokas E., Reaper P.M., Charlton P.A., Pollard J.R., McKenna W.G., Muschel R.J., Brunner T.B. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 2012;13:1072–1081. doi: 10.4161/cbt.21093. PubMed DOI PMC

Huntoon C.J., Flatten K.S., Wahner Hendrickson A.E., Huehls A.M., Sutor S.L., Kaufmann S.H., Karnitz L.M. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013;73:3683–3691. doi: 10.1158/0008-5472.CAN-13-0110. PubMed DOI PMC

Fokas E., Prevo R., Hammond E.M., Brunner T.B., McKenna W.G., Muschel R.J. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat. Rev. 2014;40:109–117. PubMed

Toledo L.I., Altmeyer M., Rask M.B., Lukas C., Larsen D.H., Povlsen L.K., Bekker-Jensen S., Mailand N., Bartek J., Lukas J. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 2013;155:1088–1103. doi: 10.1016/j.cell.2013.10.043. PubMed DOI

Johnson L.N. The regulation of protein phosphorylation. Biochem. Soc. Trans. 2009;37:627–641. doi: 10.1042/BST0370627. PubMed DOI

Tichy A., Salovska B., Rehulka P., Klimentova J., Vavrova J., Stulik J., Hernychova L. Phosphoproteomics: Searching for a needle in a haystack. J. Proteomics. 2011;74:2786–2797. PubMed

Salovska B., Tichy A., Fabrik I., Rezacova M., Vavrova J. Comparison of resins for metal oxide affinity chromatography with mass spectrometry detection for the determination of phosphopeptides. Anal. Lett. 2013;46:1505–1524. doi: 10.1080/00032719.2013.773437. DOI

Vávrová J., Zárybnická L., Lukášová E., Řezáčová M., Novotná E., Sinkorová Z., Tichý A., Pejchal J., Durišová K. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60) Radiat. Environ. Biophys. 2013;52:471–479. PubMed

Kamburov A., Pentchev K., Galicka H., Wierling C., Lehrach H., Herwig R. ConsensusPathDB: Toward a more complete picture of cell biology. Nucleic Acids Res. 2011;39:D712–D717. PubMed PMC

Kamburov A., Wierling C., Lehrach H., Herwig R. ConsensusPathDB—A database for integrating human functional interaction networks. Nucleic Acids Res. 2009;37:D623–D628. PubMed PMC

Croft D. Building models using Reactome pathways as templates. Methods Mol. Biol. 2013;1021:273–283. doi: 10.1007/978-1-62703-450-0_14. PubMed DOI PMC

Schaefer C.F., Anthony K., Krupa S., Buchoff J., Day M., Hannay T., Buetow K.H. PID: The Pathway Interaction Database. Nucleic Acids Res. 2009;37:D674–D679. doi: 10.1093/nar/gkn653. PubMed DOI PMC

Colaert N., Helsens K., Martens L., Vandekerckhove J., Gevaert K. Improved visualization of protein consensus sequences by iceLogo. Nat. Methods. 2009;6:786–787. doi: 10.1038/nmeth1109-786. PubMed DOI

Chou M.F., Schwartz D. Biological sequence motif discovery using motif-x. Curr. Protoc. Bioinforma. 2011;2011 doi: 10.1002/0471250953.bi1315s35. PubMed DOI

Schwartz D., Gygi S.P. An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. Nat. Biotechnol. 2005;23:1391–1398. PubMed

Linding R., Jensen L.J., Ostheimer G.J., van Vugt M.A., Jørgensen C., Miron I.M., Diella F., Colwill K., Taylor L., Elder K., et al. Systematic discovery of in vivo phosphorylation networks. Cell. 2007;129:1415–1426. PubMed PMC

Song C., Ye M., Liu Z., Cheng H., Jiang X., Han G., Songyang Z., Tan Y., Wang H., Ren J., et al. Systematic analysis of protein phosphorylation networks from phosphoproteomic data. Mol. Cell. Proteomics. 2012;11:1070–1083. doi: 10.1074/mcp.M111.012625. PubMed DOI PMC

Nghiem P., Park P.K., Kim Y., Vaziri C., Schreiber S.L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. USA. 2001;98:9092–9097. PubMed PMC

Mareková M., Vávrová J., Vokurková D. Monitoring of premitotic and postmitotic apoptosis in gamma-irradiated HL-60 cells by the mitochondrial membrane protein-specific monoclonal antibody APO2.7. Gen. Physiol. Biophys. 2003;22:191–200. PubMed

Toledo L.I., Murga M., Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs. Mol. Oncol. 2011;5:368–373. doi: 10.1016/j.molonc.2011.07.002. PubMed DOI PMC

Myers J.S., Cortez D. Rapid activation of ATR by ionizing radiation requires ATM and Mre11. J. Biol. Chem. 2006;281:9346–9350. PubMed PMC

Smits V.A.J., Klompmaker R., Arnaud L., Rijksen G., Nigg E.A., Medema R.H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2000;2:672–676. PubMed

Tsvetkov L., Stern D.F. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage. Cell Cycle Georget. Tex. 2005;4:166–171. doi: 10.4161/cc.4.1.1348. PubMed DOI

Fletcher L., Cerniglia G.J., Nigg E.A., Yend T.J., Muschel R.J. Inhibition of centrosome separation after DNA damage: A role for Nek2. Radiat. Res. 2004;162:128–135. PubMed

Mi J., Guo C., Brautigan D.L., Larner J.M. Protein phosphatase-1alpha regulates centrosome splitting through Nek2. Cancer Res. 2007;67:1082–1089. PubMed

Qin B., Gao B., Yu J., Yuan J., Lou Z. Ataxia telangiectasia-mutated- and Rad3-related protein regulates the DNA damage-induced G2/M checkpoint through the Aurora A cofactor Bora protein. J. Biol. Chem. 2013;288:16139–16144. doi: 10.1074/jbc.M113.456780. PubMed DOI PMC

Bertoli C., Klier S., McGowan C., Wittenberg C., de Bruin R.A.M. Chk1 inhibits E2F6 repressor function in response to replication stress to maintain cell-cycle transcription. Curr. Biol. 2013;23:1629–1637. PubMed PMC

Lin W.C., Lin F.T., Nevins J.R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001;15:1833–1844. PubMed PMC

Lau E., Tsuji T., Guo L., Lu S.H., Jiang W. The role of pre-replicative complex (pre-RC) components in oncogenesis. FASEB J. 2007;21:3786–3794. doi: 10.1096/fj.07-8900rev. PubMed DOI

Bendall S.C., Hughes C., Stewart M.H., Doble B., Bhatia M., Lajoie G.A. Prevention of amino acid conversion in SILAC experiments with embryonic stem cells. Mol. Cell. Proteomics. 2008;7:1587–1597. PubMed PMC

Ong S.E., Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC) Nat. Protoc. 2006;1:2650–2660. PubMed

Rogers L.D., Fang Y., Foster L.J. An integrated global strategy for cell lysis, fractionation, enrichment and mass spectrometric analysis of phosphorylated peptides. Mol. Biosyst. 2010;6:822–829. doi: 10.1039/b915986j. PubMed DOI

Yeung Y.G., Stanley E.R. Rapid detergent removal from peptide samples with ethyl acetate for Mass Spectrometry Analysis. Curr. Protoc. Protein Sci. 2010;2010 doi: 10.1002/0471140864.ps1612s59. PubMed DOI PMC

McNulty D.E., Annan R.S. Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol. Cell. Proteomics. 2008;7:971–980. doi: 10.1074/mcp.M700543-MCP200. PubMed DOI

Larsen M.R., Thingholm T.E., Jensen O.N., Roepstorff P., Jorgensen T.J.D. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell. Proteomics. 2005;4:873–886. PubMed

Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008;26:1367–1372. PubMed

Cox J., Neuhauser N., Michalski A., Scheltema R.A., Olsen J.V., Mann M. Andromeda: A peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011;10:1794–1805. doi: 10.1021/pr101065j. PubMed DOI

Zhou Y., Cras-Méneur C., Ohsugi M., Stormo G.D., Permutt M.A. A global approach to identify differentially expressed genes in cDNA (two-color) microarray experiments. Bioinformatics. 2007;23:2073–2079. doi: 10.1093/bioinformatics/btm292. PubMed DOI

Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006;127:635–648. PubMed

Cox J., Mann M. 1D and 2D annotation enrichment: A statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinfom. 2012;13 doi: 10.1186/1471-2105-13-S16-S12. PubMed DOI PMC

Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., Lin J., Minguez P., Bork P., von Mering C., et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41:D808–D815. doi: 10.1093/nar/gks1094. PubMed DOI PMC

Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–1075. PubMed PMC

Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes . Nature. 2007;446:153–158. PubMed PMC

Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–1355. doi: 10.1126/science.1140735. PubMed DOI

Lys05 - A Promising Autophagy Inhibitor in the Radiosensitization Battle: Phosphoproteomic Perspective

Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells

Targeting the Checkpoint to Kill Cancer Cells